Moderna, Inc. has submitted its dossier to the US Food and Drug Administration and is ready to file with other regulators for its COVID-19 vaccine candidate MRNA-1273 after unveiling a second impressive efficacy readout from the Phase III COVE study.
The latest readout bolsters hopes that the first emergency use approvals (EUAs) can come within weeks, releasing the first millions of doses before the end of 2020 to turn the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?